Publications by authors named "Tolulope Falaiye"
Article Synopsis
- Pediatric Crohn's disease (CD) is on the rise globally, and specific trends in surgical procedures for affected children have been under-researched.
- A study analyzing the Kids' Inpatient Database from 2003 to 2012 found that while overall bowel resection rates remained stable, laparoscopic colon resections increased by 41% annually, and ileostomy formation rates also rose after resections.
- Factors such as older age, male sex, fewer health issues, and treatment at large urban teaching hospitals were linked to higher chances of undergoing bowel resection, indicating a need for further research into the impact of biologic treatments on these surgical rates.
Background: Pediatric inflammatory bowel disease (IBD) care is complex and rapidly evolving. The Crohn's and Colitis Foundation of America and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition cosponsored a needs assessment survey of pediatric gastroenterology trainees and program directors (PDs) to inform on educational programming.
Methods: A Web-based, self-completed survey was provided to North American trainees and PDs during the 2013-2014 academic year.
Rising Educators, Academicians, and Clinicians Helping Inflammatory Bowel Disease (REACH-IBD)-Promoting Improvement of Inflammatory Bowel Disease Education in the United States.
Inflamm Bowel Dis
June 2016
Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.
J Pediatr Gastroenterol Nutr
February 2014
Objectives: Although randomized trials demonstrated the efficacy of infliximab for both pediatric Crohn disease and ulcerative colitis (UC), few patients in these studies exhibited colitis requiring hospitalization. The aims of this study were to determine the rate of subsequent infliximab failure and dose escalation in pediatric patients who started taking infliximab during hospitalization for colitis-predominant IBD, and to identify potential predictors of these endpoints.
Methods: This is a single-center retrospective cohort study of patients admitted from 2005 to 2010 with Crohn colitis, UC, or IBD-unspecified (IBD-U) and initiated on infliximab.